Mark C. Schneyer - 12 Sep 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, CHIEF FINANCIAL OFFICER
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
12 Sep 2025
Transactions value $
-$82,728
Form type
4
Filing time
16 Sep 2025, 18:00:19 UTC
Previous filing
19 Aug 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO /s/ Jennifer J. Rhodes, Attorney-in-Fact 16 Sep 2025 0001899977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Award $0 +6.82K +16.98% $0.00 46.9K 12 Sep 2025 Direct F1
transaction ACAD Common Stock Sale -$82.7K -3.5K -7.45% $23.65 43.4K 15 Sep 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target.
F2 The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).